RGRX Stock UPDATES Regenerx Biopharmaceuticals Inc (RGRX) 0.1500

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Regenerx Biopharmaceuticals Inc (RGRX) 0.1500 $RGRX

Epidermolysis Bullosa - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/xjhcc9/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Epidermolysis Bullosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Epidermolysis Bullosa - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Epidermolysis Bullosa pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - RegeneRx Biopharmaceuticals, Inc. - Fibrocell Science, Inc. - Birken AG - Scioderm, Inc. For more information visit http://www.researchandmarkets.com/research/xj...dermolysis

New Report: Thymosin B4 Prevents Heart Rupture & Improves Cardiac Function after Heart Attack in Mice
Business Wire - Tue Jul 15, 8:02AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that a new paper entitled, Thymosin B4 Prevents Cardiac Rupture and Improves Cardiac Function in Mice with Myocardial Infarction, was published in the journal, Heart Circulation Physiology, on July 11, 2014. "The present study shows for the first time that 1) TB4 is able to reduce incidence of cardiac rupture post-MI [myocardial infarction or heart attack] and markedly improved cardiac function at 5 weeks after MI, and that 2) the cardiac protective effects of TB4 after MI were associated with a significant reduction of excessive inflammatory response and cardiomyocyte apoptosis as well as with an enhancement of angiogenesis. From a clinical point of view, TB4 could potentially be a therapeutic candidate for patients with acute MI," according to the study's authors.

RegeneRx's Strategic Partner G-treeBNT Preparing for Phase III Dry Eye Trials in Asia with RGN-259
Business Wire - Mon Jul 07, 7:30AM CDT
RegeneRx Pharmaceuticals (OTCBB:RGRX), and G-treeBNT Co. Ltd., a Korean biotech firm, jointly announced today that G-treeBNT is preparing to file an IND and sponsor a Phase III clinical trial with RGN-259 (a Thymosin Beta 4-based preservative-free eye drop) in patients with moderate to severe dry eye initially in South Korea, followed by Japan and Australia, with follow-on registrations in certain additional Asian and Pacific Rim countries if appropriate.

RegeneRx and Lee's Pharmaceutical Dry Eye Drug Progresses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 23, 11:10AM CDT
RegeneRx Biopharmaceuticals, Inc. (RGRX) and Lee's Pharmaceutical announced that the Chinese regulatory authority has accepted a phase II investigational new drug application for RGN-259.

RegeneRx Biopharmaceuticals to begin Phase 2 trial of RGN-259 in dry eye syndrome patients in China in Q1 2015
M2 - Mon Jun 23, 5:25AM CDT
Novel therapeutic company RegeneRx Biopharmaceuticals (Other OTC:RGRX) and Lee's Pharmaceutical Holdings jointly announced on Friday that they will begin the Phase II IND for RGN-259 in patients with moderate to severe dry eye syndrome in China.

Chinese FDA Accepts Phase 2 IND for RGN-259 for Dry Eye
Business Wire - Sun Jun 22, 11:00PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("RegeneRx" and Lee's Pharmaceutical Holdings Ltd. ("Lee's" today jointly announced that the Chinese FDA has accepted a Phase II IND for RGN-259 (thymosin beta 4-based, preservative-free eye drops) to be tested in patients with moderate to severe dry eye syndrome in China.

RegeneRx Chairman, Dr. Allan L. Goldstein, to Speak at Major Drug Industry Conference
Business Wire - Tue Jun 10, 10:55AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that Dr. Allan L. Goldstein, the Company's chairman and chief scientific advisor and emeritus professor and chairman of biochemistry at The George Washington University School of Medicine, will be a plenary speaker at The Drug Discovery & Therapy World Congress 2014 in Boston, MA on Monday, June 16. Dr. Goldstein will open the meeting with a talk entitled, "Advances in Clinical Applications of Synthetic Thymosins in Treating Life-Threatening Diseases."

RegeneRx wins USD1.35m under product license and securities purchase agreement
M2 - Mon Mar 31, 5:42AM CDT
US-based RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Friday the receipt of the initial USD1.35m payment pursuant to its product license and securities purchase agreement with G-treeBNT Co headquartered in Gyeonggi-do, Korea

RegeneRx Receives $1.35 Million Pursuant to Product License And Stock Purchase Agreement
Business Wire - Fri Mar 28, 12:27PM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it received the initial $1.35 million payment pursuant to its product license and securities purchase agreement with G-treeBNT Co., Ltd (formerly Digital Aria Co., Ltd.), headquartered in Gyeonggi-do, Korea, for G-treeBNT to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. G-treeBNT purchased stock at $0.12 per share, is obligated to make an additional equity investment of $1.0 million at $0.12 per share by August 31, 2014 and retains an option until January 31, 2015 to purchase additional common stock for $825,000 at $0.15 per share. The licensing and securities purchase agreements will be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the quarter ending March 31, 2014.

RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements
Business Wire - Fri Mar 07, 6:57AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC:RGRX) ("the Company" or "RegeneRx" today announced that it has entered into two product license agreements with Digital Aria Co., Ltd., headquartered in Gyeonggi-do, Korea, for Digital Aria to develop RegeneRx's RGN-259 preservative-free eye drop product candidate in Asia (excluding China, Hong Kong, Taiwan, and Macau), and its RGN-137 topical dermal gel product candidate in the U.S. Digital Aria will also make an equity investment into RegeneRx of $2.35 million enabling RegeneRx to move forward with its ophthalmic clinical program, and retains a 10-month option to purchase additional common stock for $825,000.

RegeneRx Biopharmaceuticals wins patent for Thymosin beta 4 for treating Dry Eye Syndrome in Israel
M2 - Tue Feb 25, 5:44AM CST
Biopharmaceutical company RegeneRx Biopharmaceuticals (Other OTC:RGRX) reported on Monday the receipt of patent for Thymosin beta 4 in Israel.

RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome
Business Wire - Mon Feb 24, 9:00AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received an Israeli patent for the treatment of Dry Eye Syndrome using Thymosin beta 4 (TB4) and various fragments of TB4, as well as other analogues and derivatives. The patent will expire in 2026.

RegeneRx Biopharmaceuticals Inc awarded patent allowance in the US for neuro and muscular degenerative diseases
M2 - Fri Jan 17, 10:38AM CST
RegeneRx Biopharmaceuticals Inc (RGRX) revealed on Thursday that it has received a Notice of Allowance of a US patent application for using novel therapeutic peptide for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage.

RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases
Business Wire - Thu Jan 16, 7:30AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received a Notice of Allowance of a U.S. patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for the prevention and treatment of neuro and muscular degenerative diseases and related tissue damage. The patent will expire in 2026.

RegeneRx Biopharmaceuticals Inc awarded orphan drug designation for TB4 for treating Neurotrophic Keratopathy in the US
M2 - Mon Jan 06, 4:56AM CST
Novel therapeutic peptide developer RegeneRx Biopharmaceuticals Inc (OTC Markets:RGRX) reported on Friday the receipt of the orphan drug designation for its drug candidate, Thymosin beta 4 (T?4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium, in the US.

RegeneRx Receives Orphan Drug Designation for TB4 in the Treatment of Neurotrophic Keratopathy
Business Wire - Fri Jan 03, 7:21AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" announced that it has received Orphan Drug designation from U.S. FDA's Office of Orphan Products Development (OOPD) for its drug candidate, Thymosin beta 4 (TB4), for the treatment of Neurotrophic Keratopathy (NK), a serious degenerative disease of the corneal epithelium (the outside layer of the eye). A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision. The designation, for novel drugs to treat diseases with a prevalence of less than 200,000 patients in the U.S., provides seven years of extended marketing exclusivity, waiver of FDA user fees, tax credits of up to 50% of qualified clinical trial expenses, and eligibility of FDA research grants for clinical trials.

RegeneRx Biopharmaceuticals Inc secures Notice of Allowance for reversal of skin aging product in Canada
M2 - Mon Dec 23, 7:26AM CST
RegeneRx Biopharmaceuticals Inc (Other OTC:RGRX) reported on Friday the receipt of a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (T?4) and various fragments and other related peptides for inhibiting or reversing skin aging.

RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging
Business Wire - Fri Dec 20, 11:01AM CST
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) ("the Company" or "RegeneRx" today announced that it has received a Notice of Allowance of a Canadian patent application for using Thymosin beta 4 (TB4) and various fragments and other related peptides for inhibiting or reversing skin aging. The patent will expire in 2021.

RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa
Business Wire - Mon Jun 24, 7:30AM CDT
RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx" today announced results from its dose-escalating, double-blind, placebo-controlled Phase 2 clinical trial in 30 patients with dystrophic and junctional epidermolysis bullosa (EB), a severe "orphan" skin disorder with limited prevalence in the U.S. and Europe. RGN-137 (a topical formulation of Thymosin beta 4 or TB4) was administered to a single non-healing index lesion in these patients daily for 56 days and followed for an additional 14 days post-treatment.

Global Epidermolysis Bullosa - Pipeline Review Report, H1 2013
M2 - Fri Jun 21, 5:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hrf76c/epidermolysis) has announced the addition of the "Epidermolysis Bullosa - Pipeline Review, H1 2013" report to their offering. 'Epidermolysis Bullosa - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Epidermolysis Bullosa, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Epidermolysis Bullosa. Scope - A snapshot of the global therapeutic scenario for Epidermolysis Bullosa. - A review of the Epidermolysis Bullosa products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 102

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 0

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 0

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 28

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 116

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 215

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 0

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 126

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 49

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Line-Up of Athletes for Future Games in Abu Dhabi

Updated Category News Views 298

Global Stars Confirmed for Games of the Future 2025 Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for the ultimate showdown in next-gen sports from 18-23 December. Phygital International, the UAE-based promoter of phygital sports globally, has just confirmed the lineup for the Games of the Future Abu Dhabi 2025 (GOTF...

Continue Reading
Rhythm Pharmaceuticals Earnings Report: What to Watch For

Updated Category News Views 239

Eyes on Rhythm Pharmaceuticals: Earnings Just Around the Corner A steady hum of anticipation is in the air as Rhythm Pharmaceuticals (NASDAQ:RYTM) gears up to unveil its quarterly earnings on February 26, 2026. While investors hung onto the last report’s fallout, expectations this time are swirling around whether RYTM can turn things around after a slip last quarter....

Continue Reading
First Capital REIT Reports Impressive Q3 2024 Growth Metrics

Updated Category News Views 239

First Capital REIT's Strong Q3 Results Highlight Robust Performance First Capital Real Estate Investment Trust (TSX: FCR) has announced remarkable financial results for the third quarter ending September 30, indicating robust operational performance backed by strong leasing activities. The detailed report is made accessible to investors on the Trust's official website....

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 168

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading
Oculis Financial Results & Clinical Update for Q2 2024

Updated Category News Views 108

Oculis Reports Q2 Financial Results and Company Update Oculis Holding AG (NASDAQ: OCS; XICE: OCS), a global biopharmaceutical company focused on improving eye care, has shared its latest financial results and significant developments. The highlights from the second quarter ending June 30, 2024, illustrate the company's dedication to advancing its innovative clinical...

Continue Reading